A critical evaluation of network and pathway based classifiers for outcome prediction in breast cancer by Staiger, C. et al.
A Critical Evaluation of Network and Pathway-Based
Classifiers for Outcome Prediction in Breast Cancer
Christine Staiger1,2*, Sidney Cadot2, Raul Kooter3, Marcus Dittrich4, Tobias Mu¨ller4, Gunnar W. Klau1,5*",
Lodewyk F. A. Wessels2,3,6*"
1Centrum Wiskunde & Informatica, Life Sciences Group, The Netherlands, 2 Bioinformatics and Statistics, The Netherlands Cancer Institute, Amsterdam, The Netherlands,
3Delft Bioinformatics Lab, Faculty of Electrical Engineering, Mathematics and Computer Science, Delft, The Netherlands, 4Department of Bioinformatics, Biocenter,
University of Wu¨rzburg, Wu¨rzburg, Germany, 5Netherlands Institute for Systems Biology, Amsterdam, The Netherlands, 6Cancer Systems Biology Center, The Netherlands
Cancer Institute, Amsterdam, The Netherlands
Abstract
Recently, several classifiers that combine primary tumor data, like gene expression data, and secondary data sources, such
as protein-protein interaction networks, have been proposed for predicting outcome in breast cancer. In these approaches,
new composite features are typically constructed by aggregating the expression levels of several genes. The secondary data
sources are employed to guide this aggregation. Although many studies claim that these approaches improve classification
performance over single genes classifiers, the gain in performance is difficult to assess. This stems mainly from the fact that
different breast cancer data sets and validation procedures are employed to assess the performance. Here we address these
issues by employing a large cohort of six breast cancer data sets as benchmark set and by performing an unbiased
evaluation of the classification accuracies of the different approaches. Contrary to previous claims, we find that composite
feature classifiers do not outperform simple single genes classifiers. We investigate the effect of (1) the number of selected
features; (2) the specific gene set from which features are selected; (3) the size of the training set and (4) the heterogeneity
of the data set on the performance of composite feature and single genes classifiers. Strikingly, we find that randomization
of secondary data sources, which destroys all biological information in these sources, does not result in a deterioration in
performance of composite feature classifiers. Finally, we show that when a proper correction for gene set size is performed,
the stability of single genes sets is similar to the stability of composite feature sets. Based on these results there is currently
no reason to prefer prognostic classifiers based on composite features over single genes classifiers for predicting outcome
in breast cancer.
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Introduction
Modern high-throughput methods provide the means to
observe genome wide changes in gene expression patterns in
breast cancer samples. Gene expression signatures have been
proposed [1,2] to predict prognosis in breast cancer patients, but
were shown to vary substantially between data sets. One possible
explanation for this effect is that the data sets on which the
predictors are trained are typically poorly dimensioned, consisting
of many more genes than samples. Integrating secondary data
sources like protein-protein interaction (PPI) networks, co-expres-
sion networks or pathways from databases such as KEGG, has
recently been proposed to overcome variability of prognostic
signatures and to increase their prognostic performance [3–7].
Many of these studies claim that combining gene expression data
with secondary data sources to construct composite features results
in higher accuracy in outcome prediction and higher stability of
the obtained signatures. In addition, inclusion of the secondary
sources raises the hope that the obtained signatures will be more
interpretable and thus provide more insight into the molecular
mechanisms governing survival in breast cancer.
The underlying idea of these methods is that genes do not act in
isolation, and that complex diseases such as cancer are actually
caused by the deregulation of complete processes or pathways,
representing ‘hallmarks of cancer’ [8]. This is unlikely to happen
due to an aberration in a single gene, and often multiple genes
need to be perturbed to disable a process. This leads to the notion
that aggregating gene expression of functionally linked genes
smooths out noise and provides more power to detect deregulation
of complete functional units and hence to obtain a clearer picture
of the biological process underlying tumorigenesis and disease
outcome.
The observed improvement in classification accuracy achieved
by the approaches employing secondary data is hard to assess since
it is dependent on many factors such as the specific data sets and
evaluation protocol employed. To shed more light on this issue we
performed an extensive comparison of a simple, single genes based
classifier with three of the most popular approaches that include
secondary data sources in the construction of the classifier. More
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specifically, we included the approaches proposed by Chuang et al.
[3], Lee et al. [4] and Taylor et al. [5]. We investigated how these
methods perform with respect to classification accuracy and
stability of the set of features included in the classifiers. We will
now briefly outline how the approaches work and point out some
of the claims made by the authors. Detailed descriptions are
provided in the Methods section.
Chuang et al. [3] describe a greedy search algorithm on PPI
networks. For each defined subnetwork, a composite feature is
defined as a variant of the average of the expression values of the
genes included in the subnetwork. The score that guides the search
is the association of the composite feature with patient outcome.
Significance testing and a feature selection step are employed to
select the set of composite features used in the final classifier. The
authors claim that classification based on subnetwork markers
improves prediction performance on two breast cancer data sets.
Moreover, they state that subnetwork markers are more re-
producible across different breast cancer studies than single genes
markers.
Lee et al. [4] employ gene sets from the MsigDB database [9] as
secondary data source. The association of the composite feature
with patient outcome is used as performance criterion, and a
greedy search is employed to select a subset of genes from a gene
set to constitute the composite feature. The value of the composite
feature is derived from the expression values of the subset of genes
as defined in Chuang et al. [3]. In contrast to Chuang et al., Lee et al.
do not exploit the connectivity of the pathway in the construction
of the composite features. Lee et al. claim that by using these
pathway activities a higher classification performance can be
achieved on different cancer types, most notably leukemia, lung
and breast cancer. They also report a higher overlap between
genes in the top scoring composite features compared to the top
scoring single genes.
The underlying assumption in the study by Taylor et al. [5] is
that disease-causing perturbations disturb the organization of the
interactome, which then has an effect on outcome. They
concentrate on highly connected proteins, so-called hubs, as these
proteins act as organizers in the molecular network. In contrast to
Lee et al. and Chuang et al., Taylor et al. detect aberrations in the
correlation structure between a hub and its immediate interactors.
As correlation between two genes cannot be assessed for a single
sample, Taylor et al. employ the pairwise expression difference
between the hub and each of its interactors as features for the
classifier. While no claims are made regarding performance
improvements, we included this approach in the comparison as it
is a recently proposed, novel approach for exploiting secondary
data sources to predict outcome in breast cancer.
Table 1 provides a summary of the characteristics of all methods
included in the comparison. It lists a description of each approach,
the secondary data sources employed, the types of (composite)
features and how the value of a (composite) feature is computed for
a single tumor.
All three studies listed above use their own specific cross-
validation (CV) protocol and evaluate their method on different
(combinations of) data sets. This makes it hard to assess the im-
provement over other methods. In this work, we therefore employ
an unbiased training and validation protocol and present a com-
prehensive evaluation of cross data set classification performance
and stability on six publicly available breast cancer data sets.
Given that these classifiers are intended to predict the unknown
outcome of a patient, we suggest a cross-validation procedure that
does not assume any knowledge about the samples used for testing.
Thus, we strictly separate the training data set from the test data
set, i.e. composite feature construction, the selection of the
optimized number of features for classification and the training
of the final classifier are all performed on the training data set,
while the testing of this trained classifier is performed on a
completely separate test set without calibrating the classifier on the
test data. See Figure 1 and Algorithm 0 for details. In other words,
in contrast to previous studies, we strictly distinguish between
training and test data.
To prevent biases associated with a specific secondary data
source, we tested the algorithms on different types of secondary
data sources. (See the Materials and Methods section for detailed
descriptions of all these data sources.) We also used three different
classifier types, the nearest mean classifier (NMC), logistic
regression (LOG) and the 3 nearest neighbor classifier (3NN) to
evaluate the influence of the classifier on prediction performance.
We chose the NMC and LOG since Popovici et al. [10] confirmed
earlier findings that these classifiers performed best on various
breast cancer related classification tasks. The 3NN is included as
an example for a non-linear classifier. Similarly, different feature
extraction strategies were employed. While the included set of
feature extraction approaches is by no means exhaustive, we
employed approaches that were shown to perform well on gene
expression based diagnostic problems [11]. All evaluations were
performed on a curated collection consisting of six breast cancer
cohorts [12] including the cohort from the Netherlands Cancer
Institute [13].
Table 1. Overview of evaluated feature extraction methods.
Method Symbol Description Secondary data Feature Feature value
Single genes SG Calculates t-statistic between mRNA expression distributions
of the two patient groups
None Single gene mRNA expression of the
gene
Lee
et al. [4]
L, Lee Calculates for each pathway a set of genes with high
t-statistic between the averaged gene expression and the
two patient groups
MsigDB, KEGG Subset of genes in a
pathway
Averaged mRNA
expression of genes in set
Chuang et al. [3] C, Chuang Calculates subnetworks with high mutual information
between the averaged gene expression of the genes in the
subnetworks and the class labels of the two patient groups
KEGG, HPRD, I2D,
NetC
Genes in a subnet-
work
Averaged mRNA
expression of the genes in
the network
Taylor
et al. [5]
T, Taylor Finds hub proteins that, given the two patient groups, show
different Pearson correlation of the mRNA expression
between the hub proteins and all of their direct interactors
KEGG, HPRD, I2D,
NetC
Edge between a hub
and its interactor
Difference of mRNA
expression of hub and its
interactors (edge weights)
As secondary data sources we used the KEGG database [21] and the C2 data set of the MsigDB [9], as PPI data we used the information from KEGG, HPRD [24] and the
OPHID/I2D databases [25]. In addition we used the PPI network published by Chuang et al. [3] (NetC).
doi:10.1371/journal.pone.0034796.t001
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In contrast to earlier findings we find that when we apply a
proper correction for the number of genes appearing in the
composite features, the stability of single genes feature sets is
comparable to the stability of composite feature sets. Much to our
surprise, and in contrast to other studies, we also find that
integrating secondary data, as done in the evaluated methods, does
not lead to increased classification accuracy when compared to
simple single genes based methods. Our findings are partly
consistent with the findings of Abraham et al. [7], where the
authors show that averaging over gene sets does not increase the
prediction performance over a single genes classifier.
We investigated several possible factors that may explain the
disappointing performance of approaches incorporating secondary
data. First, we looked into the effect of the way the number of
features is selected. Second, we looked into the effect of the exact
size and composition of the starting gene set. This factor could
play a role since not all genes are included in secondary data
sources, hence classifiers employing secondary data sources may
be at a disadvantage compared to single genes classifiers that select
the gene set from all genes on the chip. Third, we investigated the
effect of sample size. Finally, since breast cancer is a collection of
genetically different diseases, heterogeneity in the microarray
studies might decrease the classification performance. We there-
fore looked into the effect of heterogeneity of the data sets on
classifier performances. We find that none of the investigated
factors change our general findings.
In addition to all these technical factors, we also investigated
whether the biological information captured in the secondary data
contributes to the classification performance of the composite
feature classifiers. To our astonishment we found that composite
classifiers constructed from 25 randomized versions of the secondary
data sources performed comparably to composite classifiers
trained on the original, non-randomized data.
We conclude that further research has to be done on finding
effective ways to integrate secondary data sources in predictors of
outcome in breast cancer. In order to facilitate this research,
and to ensure a standardized and objective way of establishing
improvements over state-of-the-art approaches, we make all the
code, data sets and results employed in this comparison available
for download at http://bioinformatics.nki.nl/staiger/software.
php.
Results
Current Composite Feature Classifiers do not Outperform
Single Genes Classifiers on Six Breast Cancer Data Sets
We compared the performance of a nearest-mean classifier
(NMC) using single genes with an NMC employing feature
extraction methods based on pathway and PPI data. The results
are depicted in Figure 2. For each combination of secondary data
source and feature extraction approach, Figure 2A shows the box
plots of the area under the receiver-operating characteristics curve
(AUC) values obtained for each pair of data sets–using one data set
of the pair as training set and the other data set in the pair as test
set. The feature extraction approaches are ranked in descending
order based on the median AUC values. The box plots suggest
that no composite classifier performs better than the single genes
classifier. Indeed, testing whether the mean performance of the
single genes classifier is different from the mean performance of
any composite classifier reveals that there is no difference (null
hypothesis can not be rejected) except for Taylor and Chuang -I2D,
where the single genes classifier is clearly superior. See Table 1 in
File S1 for details. This fact is confirmed by the pairwise
comparisons between all classifiers, see Figure 2B. A green square
means that the combination in the row won more frequently over
the combination in the column across the data set pairs. The good
performance of the single genes classifier is reflected by the fact
that the bottom row does not contain a single red box. Also, the
generally poor performance of Taylor is clearly reflected in the dark
red rows associated with this approach.
We also provide the classification results for the logistic
regression (LOG) classifiers in Figure 1 in File S1 and Table 3 in
File S1 and results for a 3-nearest neighbor (3NN) classifier in
Figure 2 in File S1 and Table 5 in File S1. In general, the
performances for both classifiers are lower than for the NMC,
with the best combination not even reaching an AUC of 0.7
while several NMC classifiers clearly exceed 0.7. For the 3NN
classifiers the mean performance of the single genes classifier is
not different from the mean performance of any composite
classifier. Apart from Lee all composite LOG classifiers perform
equally or even worse than the single genes LOG classifier.
However, it should be noted that the performance of the LOG
classifier is highly variable as a function of the number of
included features–see Figures 3–5 in File S1. In addition, the
training procedure does not converge for all feature values as is
evident in the AUC vs. number of features curves that end
abruptly. The high sensitivity to the number of features is most
evident for the Taylor composite NMCs. Clearly, the LOG
classifier as employed here (and as employed by Chuang et al. )
requires additional regularization to ensure convergence across
the whole range of feature values. Also in combination with this
classifier, Taylor performed poorly. This together with the high
computational burden associated with this method, prompted us
to omit Taylor from the remaining analyses.
Based on the results presented in Figure 2, we conclude that on
the six breast cancer data sets employed in this comparison,
composite classifiers employing secondary data sources do not
outperform single genes classifiers on the task of predicting
outcome in breast cancer, provided that a robust single genes
classifier is employed.
Figure 1. Overview of validation procedure. Input: patient-specific mRNA expression data D~(E,L) where E is an expression matrix and L a
vector with class labels; an untrained classifier; a feature extraction method and an additional secondary data source N is used in the feature
extraction method. Five fold cross-validation is used to determine the best performing number of features in the final classifier. The data set D1 is
split into five parts of which four parts are used as training set T and one part is used as test or validation set V. First T is used to extract features and
to rank them. A series of classifiers is then trained, where the number of features is gradually increased by adding features according to the ranking.
All classifiers are evaluated using V. As performance measure the area under the curve (AUC) is used. At the end of the cross-validation each of the
five splits has been used for validation once, thus we obtain five different AUC values. We choose the number of features n in the final classifier to be
the number of features corresponding to the highest mean AUC value. The best n features are determined on the whole data set D1 and the final
classifier with these features is also trained on D1 . This classifier is then tested on a different data set D3 . We evaluated all possible pairs of data sets
(f(D1,D2), . . . ,(D1,D6),(D2,D1), . . . ,(D6,D5)g) to evaluate each feature extraction method in a certain setting resulting in 30 AUC values for each
setting. These values were then analyzed in a box plot or a winchart. The features in the six classifiers (Cn of each data set) were used to determine
the stability of gene markers across different data sets.
doi:10.1371/journal.pone.0034796.g001
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Four Hypotheses Regarding the Lack of Observed
Performance Differences
Next we formulated a number of hypotheses that could explain
why classifiers employing secondary data sources do not out-
perform single genes classifiers. These hypotheses relate to (1) the
feature selection approach employed; (2) the starting set of genes
employed in each of the approaches; (3) the effect of the training
set size on performance and (4) the homogeneity of the data set
employed. In the following sections we will investigate these
hypotheses one by one.
The number of selected features does not affect relative
performances. Our cross-validation protocol employs individual
feature filtering to select an optimized number of features for the
classifier. We (Wessels et al. [11]) and others have shown that these
simple approaches perform the best in predicting phenotypes based
on gene expression data. However, we observed in the curves
showing the AUC values as a function of the number of ranked
features included in the classifier (Figures 3–5 in File S1) that the
AUC values for the NMC are very stable across a large range of
features for most approaches. This implies that the absolute maximal
AUC value chosen during the feature selection routine might only
marginally differ from the performance obtained with other feature
values. For this reason, and since the selection of the optimized
number of features introduces additional variability between the
approaches, we decided to fix the number of features to 50, 100 and
150 for most approaches. We chose these values as they covered the
feature ranges across which the performance remained stable in all
approaches. The results for fixing the number of features to 50 are
depicted in Figure 3 while results for 100 and 150 features are
presented in Figures 6 and 7 in File S1. Wilcoxon rank tests show that
no classifier using a fixed number of features performs significantly
different from its counterpart using the number of features
determined by cross-validation. See p-values of the pairwise
Wilcoxon rank test in Tables 7, 9 and 11 in File S1. As expected,
there are only minor differences between the performance of
classifiers when the number of features is restricted to 50, 100 and
150 (Tables 6, 8 and 10 in File S1) with any significant differences
favoring single genes. This confirms that the number of features is not
a critical parameter. Based on these results, we can conclude that the
number of selected features does not explain the observed differences
between composite feature classifiers and single genes classifiers.
Restricted gene sets are not detrimental to composite
feature classifiers. We next hypothesized that the lack of
difference in the performance between composite classifiers and
single genes classifiers could be caused by the fact that the
composite features are bound to the genes annotated in the
secondary data while single genes classifiers can employ all genes
on the microarray. To test this hypothesis we retrained the single
genes classifier, but restricted the set of genes from which features
for the classifier could be selected to the genes that are present in
the respective secondary data sources. The resulting classifiers are
denoted by the secondary data source from which the gene set is
derived, while the single genes classifier employing features from
the whole microarray is denoted by unrestr. The results of this
analysis are depicted in Figure 4A. There is significant difference
in the performance of the classifiers employing genes annotated in
the I2D, KEGG and MsigDB (Table 12 in File S1). However,
when accounting for multiple testing only the difference between
unrestr and I2D remains significant. Moreover, as indicated earlier,
the optimization of the number of features by cross-validation
introduces significant variation in the number of features without
resulting in large performance changes. To eliminate this source of
variation from the comparison, we fixed, as before, the number of
features to 50, 100 and 150 and repeated the comparisons. The
Figure 2. Performance of the NMC employing single genes and composite features constructed from different secondary data
sources. For each combination of feature extraction method and secondary data source and each pair of data sets we obtained one AUC value
resulting in 30 AUC values per combination. The number of features for each classifier was determined in the cross-validation procedure (CV-
optimized). A: Each box plot shows the median, the 25% and 75% percentiles and the standard deviation of the 30 AUC values. Outliers are depicted
by crosses. The boxes are sorted in descending order according to the median. B: This panel shows the result of pairwise comparisons between all
combinations of feature extraction methods and secondary data sources. If, for a given combination of training and test data set, the AUC value of
classifier i is higher (lower) than the AUC value of classifier j on the same test data set, it is counted as a win (loss) for classifier i. Element (i, j) in the
matrix represents the log2 ratio of wins to losses of method i compared to method j. Green indicates an overall win, red an overall loss and white
represents draws. The rows and columns are sorted as in Panel A. Abbreviations: SG: Single genes; C: Chuang; L: Lee and T: Taylor.
doi:10.1371/journal.pone.0034796.g002
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results are depicted in Figure 4B, and also in Figure 8 in File S1
and Tables 13–15 in File S1. We can only find significant
differences between the unrestricted single genes classifier and
KEGG when the 50 best features are selected and the I2D when
employing the 150 best features. However, both of these
differences disappear when multiple testing correction is per-
formed. We therefore conclude that the starting gene set has a
minor influence on the single genes classifiers. Hence we can reject
Figure 3. Performance of all classifiers restricted to 50 features. Comparison of the performance of the classifiers when the number of
features is trained in the CV procedure (denoted as ‘CV-opt number of features’, same values as in Figure 2) and when the 50 best scoring features
(denoted as ‘50 best features’) are selected for classification. We cannot show the values for Chuang -KEGG, Taylor -KEGG or Taylor -HPRD since for
some data sets, the number of significant composite features was lower than 50. Abbreviations of methods as in Figure 2.
doi:10.1371/journal.pone.0034796.g003
Figure 4. Comparison of single genes classifiers restricted to genes occurring in the secondary data sources. We compared the
performance of the single genes classifier trained on all genes present on the microarray ( unrestr.) with the performance of single genes classifiers
that only employ genes present in the secondary data sources. The resulting classifiers are indicated by the secondary data source whose gene set
was employed to train the classifier. A: The number of single genes was determined during the cross-validation procedure; B: the 50 best scoring
single genes were employed.
doi:10.1371/journal.pone.0034796.g004
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the hypothesis that feature extraction approaches employing
secondary data sources are put at a disadvantage since they can
not exploit the full set of genes present on the array.
Training set size has no significant effect on performance
differences. A third possible factor that could explain the lack
of performance difference between the composite feature classifiers
and the single genes classifier is the size of the training set. Recall
that in the cross-validation procedure we train on one data set and
then test on another data set. We repeat this procedure for all
possible pairs of data sets; excluding, of course, training and testing
on the same data set (paired setting). We can, however, also follow an
alternative scheme where we train on all data sets except the test
set, the so-called merged setting. More specifically, in this setting four
of the five Affymetrix data sets were merged to form a single
training data set and the fifth data set was used as test set. Thus, we
receive for each feature selection method five AUC values. This
increases the size of the training set, and by comparing the results
obtained in this setting with the results from the paired setting, we
can investigate the effect of the training set size on the classifier
performances.
Figure 5 depicts the results for the merged setting and the
pairwise setting for the CV-optimized feature sets and when only
the top 50 features are selected. (Note that, in contrast to the
results in Figure 2, this pairwise setting only employs the
Affymetrix datasets). The results for the top 100 and 150 features
are similar, see Figure 9 in File S1. Statistical testing shows that in
the paired setting (Tables 16–19 in File S1) when the number of
features is set to 150, Lee employing the MsigDB performs better
than the single genes classifier. However, this difference disappears
when correcting for multiple testing. More importantly, there are
no significant differences between the performances of the single
genes and composite feature classifiers in the merged setting
(Tables 20–23 in File S1). Hence, we can also reject the hypothesis
that the lack of performance difference is due to the sizes of the
employed training sets.
Figure 5. Classification results for merged and paired setting. In the merged setting one Affymetrix data set is set aside as test and the
remaining four Affymetrix data sets are merged into a single data set. This is repeated until every one of the five data sets acted as a test set. Top
row: Results for the merged setting. The red lines indicate the median. Bottom row: Only the five Affymetrix data sets were used in the paired
setting.
doi:10.1371/journal.pone.0034796.g005
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Dataset homogeneity affects single genes and composite
classifiers similarly. Breast cancer is a collection of several
heterogeneous diseases that show very different gene expression
patterns [14]. Expression patterns predictive of outcome might
vary between subtypes, which typically leads to problems when
training classifiers on gene expression data derived from breast
tumors. If this is not explicitly taken into account during classifier
training it could result in poor performance and unstable
classification, as the selected genes may depend on the composi-
tion of the training set. In this section we control the heterogeneity
in both the training and test sets by only selecting the relatively
homogeneous ER positive breast cancer sub-population. Since the
Figure 6. Classification results of the ER positive data only. The ER positive cases from a single data set were set aside as test set while ER
positive cases from the remaining five data sets were merged into a single training set. This was repeated until each data set was employed as left-
out test set, resulting in six AUC values. The red lines indicate the median. A: CV-optimized number of features; B: 50 best features.
doi:10.1371/journal.pone.0034796.g006
Figure 7. The effect of randomized secondary data sources. Left: AUC values obtained with the feature extraction method Lee on real and
randomized MsigDB pathways. Right: AUC values obtained with the feature extraction method Chuang on real and randomized PPI networks.
doi:10.1371/journal.pone.0034796.g007
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training sets become too small in the paired setting if we only select
the ER positive cases, we followed the merged setting outlined
above. More specifically, we created a test set consisting of all ER
positive cases of a single data set and a training set by pooling all
ER positive cases from the remaining data sets. We repeated this
procedure across the six data sets and thus obtained six AUC
values per classifier. Figure 6 depicts the results for the CV-
optimized feature sets and the top 50 features. As before, the
Figure 8. Feature stability when the top 50 features are selected. For each method the Fisher exact test was employed to compute a p-value
representing the overlap between the gene sets extracted from two different data sets. This was repeated for all pairwise combinations of data sets,
resulting in 15 values. It should be noted that we do not employ the Fisher exact test as a hypothesis test. Instead we interpret the p-values as a
measure of overlap between two sets of marker genes. The figure shows the box plots for each method and the individual values (grey dots).
doi:10.1371/journal.pone.0034796.g008
Figure 9. Feature stability when corrected for gene set size. Box plots of the p-values of the Fisher exact test computed for all pairs of gene
sets derived from two different data sets. The green box plots represent the values for genes constituting composite features, while the blue box
plots (denoted as ‘Control for size SG’) represent the gene-size-corrected values for single genes classifiers. The white stars represent the means of the
distributions.
doi:10.1371/journal.pone.0034796.g009
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classifiers employing a fixed number of features perform similar to
classifiers based on a feature set optimized in the CV procedure.
See Figure 6B, and also Figure 10 in File S1. In general, and in
accordance with earlier observations as made, e.g., by Popovici et al.
[10], the performance of all classifiers is substantially better on the
ER positive cases compared to the unstratified case. More
importantly, also in this setting there are no significant performance
differences between the single genes classifiers and composite
feature classifiers (Tables 24–27 in File S1).
Equal Classification Using Real or Randomized Networks
and Pathways
In the previous sections we showed that composite classifiers do
not perform significantly better than classifiers employing single
genes as features. We investigated several factors that could
influence the performances of these two approaches, but failed to
find any factor that induces significant performance differences on
the data sets we employ in this study. This lead us to question
whether prior knowledge sources really contain information that is
of value in constructing features for classifiers predicting outcome
in breast cancer. Chuang et al. [3] compared their PPI-based
classifier to classifiers derived from randomized PPI networks.
They concluded that their classifier performed significantly better
than random classifiers. We decided to repeat this analysis for a
subset of the classifiers in our comparison to determine whether
prior knowledge sources really contain information relevant for
predicting outcome in breast cancer. To this end, we generated,
for each prior knowledge source, 25 random instances. More
specifically, we maintained the structure of the pathways, networks
and gene sets, and randomly permuted the identities of the genes.
In doing so, the original topology of the secondary data is
preserved while the biological information is destroyed. We then
repeated the whole validation procedure on all 25 random
instances for the feature extraction methods Lee and Chuang. The
results of this analysis are presented in Figure 7. Strikingly,
classifiers derived from secondary data sources suffer no significant
performance degradation when employing randomized secondary
data sources. The performance of Chuang on randomized PPI data
clearly has a large variance, and there are instances of classifiers
derived from random networks that perform much worse and
much better than classifiers derived from the non-randomized
networks. Furthermore, we found that most classifiers based on
randomized secondary data show performances similar to the
classifiers derived from the non-randomized secondary sources. To
formalize this observation, we performed a statistical test. We have
reason to believe that the results derived from the real data should
be better than the results derived from random data. Hence we
performed one-sided paired Wilcoxon rank tests to determine
whether the null hypothesis that the mean ‘non-randomized’
AUC-value is larger than each of the the 25 ‘randomized’ mean
AUC-values can be rejected. We performed a Bonferroni
correction to account for multiple testing. The results in Figures
11–13 in File S1 and Tables 28–33 in File S1 show that in the vast
majority of the cases the null hypothesis can not be rejected.
Conversely, it is very simple to generate a randomized secondary
data source that performs equally well as the real data source. This
result shows that further research must be done on the utility of
secondary data sources in predicting breast cancer outcome.
Current Composite Feature Classifiers do not Increase the
Stability of Gene Markers
Apart from performance improvements, it is also frequently
claimed that features derived from classifiers employing secondary
data sources are far more stable than single genes classifiers. In
other words, whereas single genes signatures extracted from
different data sets show very little overlap, features extracted by
approaches that employ secondary data sources are claimed to
show a large degree of overlap, even though the features were
derived from separate data sets. We determined whether feature
sets extracted from secondary data sources do, in fact, show a
larger degree of stability than single genes feature sets. We
employed the Fisher exact test as a measure of overlap. We use the
Fisher exact test since it has the desirable property of automatically
compensating for the size of the population from which the
signatures, for which the overlap is being computed, are selected.
Here, taking these sizes into account is crucial since the starting
gene sets defined on the one hand by the genes present on the
microarray (single genes approach) and on the other hand by the
secondary data sources (composite features) vary immensely.
Please note that in this specific context we do not employ the
Fisher exact test to test a certain hypothesis. We rather interpret
the p-values returned by the test as a measure of enrichment or
overlap between two sets of marker genes. Thus, the smaller the p-
value the more unlikely the overlap. In addition to the Fisher exact
test, we calculated the overlap between gene marker sets by
employing the Jaccard index and compensated for the size of the
population from which the signatures were selected by a random
sampling procedure. See Section 7.2 in File S1 for more details.
We performed the overlap comparison for the cases where the top
50, 100 and 150 features are selected. Figures 8 and 15 in File S1
illustrate the results for the Fisher exact test. To assess whether
there exist differences in the distributions, we performed Wilcoxon
rank tests (see Table 34 in File S1). Indeed, these results confirm
that Chuang-NetC, Chuang-IPP and Chuang-HPRD produce more
stable gene signatures across datasets. However, strictly speaking,
such a comparison compares the proverbial apples and oranges,
since a single composite feature can contain many genes. In order
to ensure that the low overlap of single genes is not only due to the
fact that the best single gene feature sets contain fewer genes than
the other feature sets, we controlled the single gene feature sets for
size. More specifically, for each data set and each feature selection
approach employing secondary data sources, we obtain a single
best feature set consisting of n features (networks, gene sets or
pathways) where each feature, in turn, consists of m genes. We
then determine a size-matched single genes set by choosing the
best m single genes on that same expression data set. The results
are shown in Figures 9 and 16 in File S1 for the Fisher exact test
and in Figure 17 in File S1 for the approach combining random
sampling with the Jaccard index. The Wilcoxon rank test on the
Fisher exact results (Tables 35–37 in File S1) shows that only
features determined with Lee -MsigDB have a higher overlap
between datasets than the single genes sets. For the approach
combining random sampling with the Jaccard index (Tables 38–40
in File S1) none of the composite feature approaches shows a
significantly larger overlap than the single genes approaches. In
fact, in four of the 14 experiments single genes approaches show a
significantly larger overlap (after correcting for multiple testing)
than the Lee approach. We can therefore conclude that - when
properly size matched - singe genes classifiers produce feature sets
that are at least as stable as composite feature classifiers.
Discussion
In this study we evaluated the prediction performance of
network and pathway-based features on six breast cancer data sets.
In contrast to previous studies we found that none of the classifiers
employing composite features derived from secondary data sources
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can outperform a simple single genes classifier. Moreover, we did
not find any evidence that composite features show a higher
stability across the six breast cancer cohorts. Our findings suggest
that with the feature extraction methods tested in this study, we
cannot extract more knowledge from secondary data sources than
we find in the expression of single genes.
There are several issues that could potentially contribute to that
situation. First, secondary data sources are, to a large degree,
generated by high-throughput biological experiments and could
thus contain a level of noise that deems them inappropriate for
outcome prediction in breast cancer. On the other hand, the
search algorithms could be unsuitable to detect biologically
meaningful networks. All three feature extraction methods only
extract local information without taking into account the full
structure of the network or pathway data. This local information is
then combined in the classifiers in a rather crude way, namely by
simply averaging the expression of the genes associated with a
feature that was found to be associated with outcome, i.e. treating
each single sub-network or sub-pathway as a single dimension in
the classification space. Possible dependencies between features are
not taken into account. Also, exploring the subnetwork search
space in a heuristic manner may decrease classification perfor-
mance. The recent method by Dittrich et al. [15] computes
provably maximally deregulated connected subnetworks based on
a sound statistical score definition. This method has not yet been
used for classification.
Other recent algorithms as presented by Ulitsky et al. [16],
Chowdhury et al. [17] and Dao et al. [18] search for deregulated
subnetworks in subsets of samples. These subnetworks are sets of
genes that are deregulated in most, but not necessarily all, patients
with poor disease outcome. The heuristic method by Chowdhury
et al. [17] has been shown to perform well on cross-platform
classification of colorectal cancer outcome. Dao et al. [18] improved
on these results by exact enumeration of all dense subnetworks with
the above-mentioned property. Looking at subsets of samples in a
class, i.e. a subset of the poor outcome samples, is an interesting
aspect for further evaluation, in particular for breast cancer
outcome prediction as it may quite accurately capture the large
phenotypic variety of this rather inhomogeneous disease.
Lee et al. [4] and Chuang et al. [3] average the expression values
of single genes comprising a subnetwork, to determine the ‘activity’
of the subnetwork. This is, however, a very simplistic view of
the dynamics in a subnetwork itself. In contrast to these two
algorithms, the method by Taylor et al. [5] predicts outcome by
trying to capture the disruption of the regulation of a hub protein
over its interactors in poor outcome patients. This is implemented
by using every edge leading to a hub as a feature in classification
space. Yet, in this way, the classification space becomes too large
to allow for good classification results. This method is thus not
appropriate for solving the classification problem and this is clearly
demonstrated by the poor performance of this algorithm in the
comparison.
To find a subnetwork scoring function remains one of the
biggest problems when including promising gene sets into a
classification framework. Abraham et al. [7] tested the classification
performance of gene sets provided by the MsigDB. The authors
employed several set statistics like mean, median and first principle
component to score the gene sets. They found that none of the
classifiers employing gene sets and scoring them with the set
statistics performed better than a single genes classifier.
In our experiments where we shuffle the genes in the secondary
data we showed that features determined on this nonsensical
biological data perform equally well in classification than features
determined on the real secondary data. This again could possibly
be caused by the low quality of the network and pathway data.
However, the nature of gene expression patterns in breast cancer,
and specifically its association with outcome can also explain these
findings. Since many genes are involved in breast cancer and are
differentially expressed and associated with outcome, as shown, for
example by Ein-Dor et al. [19], the chance that those genes span
decently sized subnetworks in the randomized secondary data is
high. Both algorithms, Chuang and Lee, look for highly differentially
expressed subnetwork or pathway markers, and these can also be
found in the randomized data. Furthermore, overlaying networks
or pathways that contain protein level information with mRNA
expression data might result in erroneous results. These data
sources reflect events on very different molecular levels. While
gene expression and protein expression is undoubtedly linked,
there are many processes that prevent this from being a trivial one-
to-one mapping. Thus, we may measure, for a set of genes, an
effect on the mRNA level that leads to differential expression
between the two patient classes but this may have little bearing on
the relationships between these genes as captured in the PPI
graph. In conclusion, our results show that it may not be sufficient
to search for sub-networks or sub-pathways that are differentially
expressed on average but that complex interactions between entities
as well as the more complicated relationships between mRNA
levels and the topology of the PPI graph need to be taken into
account.
Our different classification results are partially owed to the fact
that we used a different cross-validation procedure, which, in our
opinion, fits the clinical situation, better. The studies by Chuang
et al. [3] and Lee et al. [4] also determined possible features on one
data set. However, in contrast to our work they reranked the
features on the second (test) data set. Furthermore, they de-
termined the number of features and the classification perfor-
mance on this second data set using five-fold cross-validation. In
our opinion, this does not represent a bona fide independent
validation of the classifier as the training and test sets are not
strictly separated. An advantage of the approach employed by
Chuang et al. [3] and Lee et al. is that differences between
platforms can more easily be accommodated. This is less of a
problem in our study as five of the employed datasets in our study
come from the same Affymetrix platform (U133A) and only one
dataset from the Agilent platform. Figure 5 (pairwise setting) and
Figure 2 show that the influence of the single Agilent dataset on
the classification result is only mild and affects all of the feature
extraction methods in a similar fashion.
Also the usage of various types of classifiers in this study
contributes to the different findings. Here we tested the NMC,
LOG and a 3NN classifiers. While the LOG classifier generally
performed much worse than the NMC, it did yield better
classification results when employing features extracted with Lee.
In general, this hints at the fact that the choice of classifier
influences the ranking of the feature extraction methods. However,
the NMC and 3NN achieved similar performances for all feature
extraction methods. Moreover, in accordance with Popovici et al.
[10], we found that a simple NMC performed best, independent
from the feature extraction method.
In summary, we introduced a framework to test the use of
feature extraction methods with respect to the prediction of their
determined features. We used this framework to specifically test
the superiority of feature extraction methods based on network
and pathway data over classifiers employing single genes. Across
six breast cancer cohorts, we showed that the three tested methods
do not outperform the single genes classifier nor do they provide
more stable gene signatures for breast cancer.
Critical Evaluation of Breast Cancer Classifiers
PLoS ONE | www.plosone.org 11 April 2012 | Volume 7 | Issue 4 | e34796
An important aspect that hampers progress in the field of
network and pathway based classification is the lack of proper
evaluation of proposed algorithms. In our opinion this is caused by
(1) lack of reproducibility of the results; (2) lack of large and
standardized benchmark sets to test proposed algorithms and (3)
lack of a standardized, unbiased protocol to assess the perfor-
mances of proposed methods on the benchmark sets. To overcome
these issues, we have created a software pipeline that implements
all the classifiers as faithfully as possible and also runs our
validation protocol. We have also established a large collection of
breast cancer datasets (and this is currently being expanded) on
which the algorithms can be tested. Both the datasets and the
pipeline are freely available. In the long term, we envision a web
service where a classifier can be submitted as a software package.
The server will then autonomously evaluate the performance of
the classifier using the standardized pipeline on the benchmark set.
Materials and Methods
Microarray Data
The microarray data sets used in this work is listed in Table 2.
To combine the five Affymetrix arrays with the Agilent arrays we
first matched the probes on the arrays to Entrez GeneIDs. Only
those genes were included in the feature sets that appeared on both
platforms, resulting in 11601 genes in total. In case that several
probes on one chip matched to the same gene the expression
values of the probe with the highest variance was taken. The final
expression matrices were then z-normalized such that the
expression distribution of each gene has a mean of zero and a
standard deviation of one. Samples in the data sets were labeled
‘good’ outcome if no event, that is, a distant metastasis or death,
occurred within five years. Otherwise samples were labeled ‘poor’
outcome.
We found that probes matching several geneIDs in the
Affymetrix datasets were not discarded, instead the smallest
geneID was used to map the probe to a certain gene. This could
potentially influence the mapping from gene expression to the
network or pathway data and thus, influence the classification
result and overlap of gene markers. However, classification on the
corrected expression data, i.e., removing these ambiguous probes
from the expression matrices and re-executing our cross validation
procedure for all of the methods, yielded the same performances
and overlap between markers. ER status of patients was predicted
from the expression values of the gene ESR1. For more detail of
the processing of the data see van Vliet et al. [20]. In Section
‘Dataset homogeneity affects single genes and composite classifiers
similarly’ we merge datasets to obtain a larger training dataset.
This merging was done by pooling all patients from all but one
dataset, followed by a z-normalization of the merged datasets.
Network and Pathway Data
All feature extraction methods were run on the databases
KEGG [21] and HPRD [22]. The algorithm by Lee et al. [4] was
also run on the MsigDB C2 database [9].
KEGG. We collected all pathway information available for
Homo sapiens (hsa) from the KEGG database, version December
2010. The entries contained information on metabolic pathways,
pathways involved in genetic information processing, signal
transduction in environmental information processing, cellular
processes and pathways active in human disease and drug
development. We obtained 215 pathways. The nodes contained
in the pathways were matched with the KEGG gene database
such that each node carries an Entrez GeneID. In this way we
obtained a network composed of 200 pathways containing 4066
nodes and 29972 interactions of which 3110 nodes are also
contained in the expression sets.
MsigDB. As second pathway database we used the C2
collection of the MsigDB (version 3) [9], which was also used in
Lee et al. [4] (version 1.0). It contains gene sets from online
pathway databases such as KEGG, gene sets made available in
scientific publications and expert knowledge. We obtained 3272
gene sets of which 2714 could be entirely or partially mapped the
six data sets. The MsigDB does not contain any edges, thus this
database was only usable for the algorithm by Lee et al. [4].
HPRD. The HPRD (version 9) provides information on
protein-protein interactions (PPI) derived from the literature. The
HPRD contains 9231 proteins and 35853 interactions. The
proteins were mapped to their genes carrying Entrez GeneIDs.
There are 7390 genes contained in both the HPRD and the
expression sets.
OPHID/I2D. The OPHID/I2D database, downloaded in
April 2011, contains protein-protein interactions derived from
BIND, HPRD and MINT as well as predicted interactions from
yeast, mouse and C. elegans. The database contains 12643 nodes
and 142309 edges. 9453 of the nodes are also present in the six
breast cancer studies examined here.
Protein-protein interaction network by Chuang et al. [3]
(NetC). The network curated by Chuang et al. [3] consists of
57228 interactions and 11203 nodes of which 8572 are contained
in the six breast cancer studies. The network is curated from
yeast two hybrid experiments and interactions predicted from
co-citation.
Algorithms
Notation. Let Ek|n be a gene expression matrix, as we obtain
it from a microarray study, with k samples and n genes. Each entry
ei,j contains the expression value of gene j in sample i. All samples
carry a binary class label li[f0,1g denoting outcome, where 1
denotes ‘poor outcome’ and 0 denotes good outcome’. The label
vector of all samples is denoted by L~(l1, . . . lk)
T . We denote a
network by N~(G,I) where G is the set of genes in the network
and I is the set of interactions between these genes, also called
edges in the following. We define a subnetwork as the connected
graph N ’~(G’,I ’) with G’(G and I ’(I , and a pathway as a gene
set G’(G. Let G’ be such a pathway or the set of genes in a
subnetwork then according to [3,4] the activity of the pathway or
subnetwork in sample i is given as
Table 2. Microarray expression data.
Dataset Outcome good/poor platform
Chin [26] Metastasis within 5 years 68/29 Affymetrix
Desmedt [27] Metastasis within 5 years 91/29 Affymetrix
Loi [28] Metastasis within 5 years 92/28 Affymetrix
Miller [29] Death within 5 years 156/37 Affymetrix
Pawitan [30] Death within 5 years 120/22 Affymetrix
Vijver [13] Metastasis within 5 years 178/70 Agilent
Expression data used in this study. All data sets were processed as described in
[20] and contained 11601 genes with z-normalized expression values
afterwards. Column ‘poor/good’ contains the number of samples with poor or
good outcome, respectively.
doi:10.1371/journal.pone.0034796.t002
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Feature extraction method by Chuang et al. [3]. Given a
network N~(G,I), the algorithm by Chuang et al. [3] carries out a
greedy search starting from a seed–a single gene in the network. It
then iteratively extends the network by adding neighboring genes
to find subnetworks with high mutual information (MI) of the
activity of the pathway and sample labels. Each node in N is used
once as seed. In each step, an additional gene is picked that leads
to a maximal MI improvement. If no improvement is possible, the
search stops.
More precisely, the association between the subnetwork activity
and the class labels is computed as follows: Given a subnetwork
N ’~(G’,I ’) the activity vector aG’~(aG’,1, . . . ,aG’,k)
T is calculated
using Equation (1). To compute the MI, vector aG’ is discretized.
Given a dissection of the interval ½mini[½1,...,k aG’,i, maxi[½1,...,k aG’,i
into qlog2 kr bins let d : R?½d1, . . . ,dqlog2 kr be a function that
assigns a network activity to a sample with one of these bins, where
di, i~1, . . . ,qlog2 kr, denote the bins. We define the mutual
information sMI between the probability density of the bins p(d(:))
and the probability distribution of the class labels p(l) as
sMI (d,l)~
Xqlog kr
i~1
X1
l~0
p(di,l) log
p(di,l)
p(di)p(l)
ð2Þ
where p(di,l) is the joint distribution of p(d(:)) and p(l): The
algorithm also performs three statistical tests to extract only
networks that show significantly high mutual information. The
ranking of the networks is given by ordering the networks
according to their mutual information sMI .
In our study we use PinnacleZ, an implementation of the
algorithm provided by the authors. As feature values for clas-
sification the subnetwork activity as given in Equation (1) of the
determined subnetworks was used.
Before determining the subnetworks, PinnacleZ performs a z-
normalization of the given data set. This is undesirable when
looking at subsets of data sets as we do in the five-fold cross-
validation. In order to skip the normalization step, we implement-
ed a patch in the PinnacleZ source code. This patch adds a ‘‘-z’’
option that instructs PinnacleZ to omit its usual gene-wise z-
normalization step.
One problem when mapping the expression data to the network
data is that for some nodes there is no expression data. Chuang
et al. [3] do not state in their paper how they handled this problem
although their identified subnetworks contain such nodes. We
therefore filtered out proteins for which no expression data is
available before running PinnacleZ. For further issues we
encountered when working with PinnacleZ see File S1.
Algorithm by Lee et al. [4]. The algorithm by Lee et al. [4]
uses the t-statistic to rank pathways according to their overall
differential expression. For this it first defines sets of genes, the so
called condition responsive genes (CORGs), which contain the
most differentially expressed genes of a pathway. These genes are
found by applying a greedy search. For each pathway the genes
are ordered according to their t-statistics. Given the two sample
groups let E1j be the expression values of gene j for all samples with
class label 1 and E0j the expression values of gene j for all samples
with class label 0, respectively. Let k0 and k1 denote the number of
samples in each group; mE0
j
and mE1
j
denote the means of the two
groups and sE0
j
and sE1
j
the standard deviation in the two groups.
The t-statistics between E1j and E
0
j is given by
t(j)~
m
E1
j
{m
E0
jﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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The genes in a pathway are sorted either in ascending order, if
the highest absolute t value is negative, or in descending order, if
the highest absolute t value is positive. Given this order the greedy
search iteratively combines genes and calculates their average
expression, or pathway activity, across the samples as it is given in
Equation (1), i.e. aG’~(aG’,1, . . . ,aG’,k)
T is calculated where G’
contains the best m genes according to the ranking. To evaluate
the combined discriminative power of the genes that have been
averaged, the t-statistic of the averaged expression is computed as
follows:
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where m
a0
G’
and m
a1
G’
represent the means and s
a0
G’
and s
a1
G’
represent the standard deviations of the averaged activities. If the
resulting value t(G’) is higher than the previous value of the t-
statistics then the search continues adding the gene to the already
determined CORGs, otherwise the search stops. The score sG’ of
the final CORGs G’ is then used to rank the pathway.
As mentioned beforehand, Lee can only be executed on
predefined gene sets. Those gene sets are normally not provided
in a PPI database. Thus, we used the KEGG and MsigDB
databases to evaluate this algorithm. In order to decrease the
running time the authors executed a pathway ranking by
employing the algorithm by Tian et al. [23] and just taking the
top 10% of pathways into account prior to executing their
algorithm. In our setting we ranked all of the pathways according
to the algorithm by Lee et al. [4] and considered for determining
the optimized number of features in the final classifier all pathways
in KEGG and the top 400 pathways in MsigDB. As feature values
for classification the pathway activity, as computed according to
Equation (1) for all condition-responsive genes (CORGs), is
employed. Here again we excluded proteins in the pathways for
which no expression data is available.
Algorithm by Taylor et al. [5]. In contrast to the algorithms
by Chuang et al. [3] and Lee et al. [4], the algorithm by Taylor et
al. [5] first identifies organizer proteins in the network, the so-
called hubs, and then attaches a weight to each edge between the
hubs and their direct neighbors in the network. These weights are
later used to train a classifier.
Candidate hubs are the 15% most densely connected proteins in
the network data, independent from their expression status. For
the following calculations proteins without expression data are
excluded. To identify hubs that significantly change their
interaction behaviour between the two classes the authors
introduce the hub difference and the average hub difference
which are based on the Pearson correlation. The Pearson
correlation between a hub h and an interactor n of this hub is
defined as the Pearson correlation between their expression
profiles across the k samples
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P(h,n)~
Pk
i~1
(en,i{mEn )(ei,h{mEh )
(k{1)sEnsEh
: ð5Þ
En and Eh denote the distribution of expression values across
the k samples and m and s are their means and standard
deviations. The hub difference is defined as the difference of the
Pearson correlation P(h,n) given the two sample classes, indicated
by the superscript 0 and 1,
d(h,n)~P0(h,n){P1(h,n): ð6Þ
Let d(h) denote the set of neighbors of a hub h then the average
hub difference is
d(h)~
P
n[d(h)
Dd(h,n)D
Dd(h)D
: ð7Þ
To extract only those hubs that show a significant average hub
difference the value is compared to a distribution of the average
hub difference for a permuted dataset, using a p-value cut off of
0.05. This distribution is calculated by 1) randomly permuting the
class labels and 2) recalculating the average hub difference and
repeating these two steps 1000 times. The significant hubs are
ranked by their average hub difference.
As feature values in the classifier differences of the expression of
the hub and each of its interactors were used. For example,
suppose h1, . . . ,hp were found significant and suppose.
(h1,i1,1), . . . ,(h1,i1,m1 ), . . . ,(hp,ip,1), . . . ,(hp,ip,mp ) are the edges
to their interactors. Then for one sample the vector
(eh1{ei1,1 , . . . ,eh1{ei1,m1 , . . . ,ehp{eip,1 , . . . ,ehp{eip,mp ) contains
the feature values for the classifier.
Since the edges attached to a hub are not ranked, all those
edges were included in the classifier, given that the hub shows a
significant average hub difference. For the cross-validation
procedure this means that we can not train the number of features
but only a number of feature sets.
Classifiers. In our study we employed a nearest mean
classifier (NMC), logistic regression (LOG) and a 3-nearest
neighbor classifier (3NN). As distance metric for the NMC we
employed the Euclidean distance. More specifically, a sample is
projected on the line connecting the two class means, and the
Euclidean distance of the projected sample to each class mean is
computed. The sample is assigned to the closest class. In addition
to the NMC we executed all features extraction methods in
combination with the LOG. We found that simple LOG without
any regularization parameters cannot be trained properly since for
higher numbers of features (approximately 50 features and more)
the training step does not converge on the breast cancer data.
Moreover, we found that for many features different im-
fplementations of LOG return different weight vectors. Thus, we
used three different implementations (the R GLM, R NNET and
Python SciKits implementation) and only accepted the classifica-
tion result of the R GLM implementation when all three versions
converged to the same weight vector. Furthermore, we tested the
classification performance of pathway and network based features
and single genes in a 3-nearest neighbor classifier (3NN). As
distance metric we chose the Euclidean distance. Further, we
weighted the contribution w of each neighbor to a sample’s score
by
wj~
1
djze
, ð8Þ
where dj denotes the Euclidean distance of the jth neighbor and
~0:000001. The results of this classifier are presented in the
Supplement Section 1.2.
Cross-validation and classification. In the cross-validation
procedure we employed, we rigorously separate the training and
test data sets. For details, see Figure 1 and Algorithm 1.
Algorithm 1. Cross-validation procedure.
Require: Datasets D1~(E1,L1), D2~(E2,L2) where E1,E2
are expression matrices and L1,L2 are vectors of outcome labels.
Feature extraction method m[fSG,L,C,Tg:
Secondary data source N.
Classifier C[ {logistic regression, nearest mean classifier, 3-
nearest neighbour classifier}.
/* Cross-validation on D1 */.
1: (d1,d2,d3,d4,d5)/D1 split samples in D1 into 5 parts dk~(ek,lk)
where ek denotes the expression values of the samples in split k and
lk their class labels */
2: for s/1 to 5 do
3: Val/ds/*validation set (eval ,lval) */
4: Train/D1\ds training set etrain,ltrain */
5: rankedF/m(Train,N) determine features according to the
published methods and rank them according to the appropriate
score or determine the ranking of the single genes according to the
t-statistic on Train */
6: n/ number of rankedF
7: AUCs = empty list
8: for i/1 to n do
9: Cs,i/trainCl(C,rankedF ½1, . . . ,i,Train) train the classifier
with i features */
10: p^/Cs,i(eVal) ranking of the samples in the validation set */
11: AUCs,i/calcAUC(p^,lVal) calculate AUC value for Cs,i */
12: end for
13: end for
/* train CV-optimized classifier on D1 and validate it on an
independent data set D2 */.
14: for j/1 to n do
15: meanAUC½j/mean(AUC1½j,    ,AUC5½j)
16: end for
17: n/argmaxjmeanAUC½j
18: networks/m(D1,N)
19: Cn/trainCl(C,rankedNWs½1, . . . ,n,D1)
20: p^/Cn (E2)
21: AUC/calcAUC(p^,L2)
22: return AUC
The training phase consists of determining the best performing
number of features and training the final classifier with this
number of features. The trained classifier is then tested in the test
phase. The data sets used in these two phases are completely
independent, i.e. the test set is never used in training the classifier.
To determine the optimized number of features in our classifiers
we employed five fold cross-validation. In this cross-validation, we
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first determined all required composite features (if necessary) and
their ranking on four splits of the training data set. Then a series of
classifiers is trained on the same four splits by gradually adding
features according to the ranking. These classifiers are then
evaluated on the fifth split of the data set. Since this is done in a
five fold cross-validation we obtain for each of the classifiers five
different AUC values. The optimized number of features extracted
corresponds to the number of features yielding the highest mean
performance. Once the best performing number of features is
determined, the features are calculated using the whole training
data set and the final classifier is trained also using the complete
training data set. The classifier is then tested on the test data set.
For each method we used all possible pairs of data sets as training
and test set respectively. Since we have six data sets available this
resulted in 30 AUC values for each method.
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